Accordingly, in the regulation network whose function can be interfered with, Mir-146a is found to be a negative regulator of RIPK2, which further exerts anti-tumor effects on CRC through RIPK2 inhibition and the following limitation on bone marrow-mediated inflammatory IL-17 production and IL-17 signaling transduction (Garo et al., 2021). Here, RIPK2 is linked to neoplasm.